OYST News and Press, Oyster Point Pharma Inc. From 11/05/20

Oyster Point Pharma (OYST): Q3 GAAP EPS of -$0.63 beats by $0.11.Cash and cash equivalents of $214.3M.Press Release For further details see: Oyster Point Pharma EPS beats by $0.11

OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease Remains on Track for Q4 2020 OC-01 Investigational New Drug (IND) Application Submission to FDA for Neurotrophic Keratitis (NK) Remains on Track for...

PRINCETON, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

Ali Behbahani, M.D. takes on role of Chairperson of the Board Michael G. Atieh joins the Board of Directors as Chair person of the Audit Committee PRINCETON, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a cli...

PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced t...

Oyster Point Pharma, Inc. (OYST) Q2 2020 Earnings Conference Call August 05, 2020 08:30 AM ET Company Participants Daniel Lochner – Chief Financial Officer Jeffrey Nau – President & Chief Executive Officer John Snisarenko – Chief Commercial Officer Con...

Image source: The Motley Fool. Oyster Point Pharma, Inc.   (NASDAQ: OYST) Q2 2020 Earnings Call Aug 05, 2020 , 8:30 a.m. ET Operator Continue reading

Oyster Point Pharma (NASDAQ: OYST ) : Q2 GAAP EPS of -$0.66 beats by $0.15 . More news on: Oyster Point Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020 Cash and Cash Equivalents of $226.7 million as of June 30, 2020 Conference Call and Webcast Scheduled for 8:30 am ET today...

PRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...